The risk of breast cancer for PALB2 mutation carriers has been studied worldwide in various populations; the risk of developing breast cancer was six times higher (CI = 2.2–17.2; p = 0.01) in Finnish families carrying the c.1592delT founder mutation as compared to the risk of developing non-breast cancer, which was 1.4 (CI = 0.6–3.2; p = 0.5) times against normal individuals [39]. Here, PALB2 is linked to breast carcinoma.